Serono Luveris Committee Calls For Better FDA-Sponsor Communication
Executive Summary
FDA's Reproductive Health Drugs Advisory Committee urged better communication between FDA and sponsors at the review of Serono's Luveris for infertile hypogonadotropic hypogonadal women with severe luteinizing hormone deficiency